NCT01419704撤回1 期
Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies
适应症
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 6
- 主要终点
- Proportion of Hemoglobin A and S
研究概览
简要总结
The goal of this research study is to establish chimerism and avoid graft-versus-host disease in patients with hemoglobinopathies.
详细描述
This proposal is a phase I/II feasibility study to demonstrate that mixed chimerism can be established with minimal risk in recipients with hemoglobinopathies treated with Campath-1H-based nonmyeloablative conditioning and graft engineering to reduce the risk of Graft Versus Host Disease (GVHD), but preserve engraftment of donor cells.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 45 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Proportion of Hemoglobin A and S
时间窗: one month to three years
Red blood cell contents by hemoglobin electrophoresis
次要结局
- Enriched Hematopoetic Stem Cell Engraftment(One month to three years)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
1 期
Phase I/II Pilot Study of Mixed Chimerism to Treat HemoglobinopathiesSickle Cell DiseaseNCT00777231Talaris Therapeutics Inc.9
终止
1 期
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic DisordersHurler Syndrome (MPS I)Hurler-Scheie SyndromeHunter Syndrome (MPS II)Sanfilippo Syndrome (MPS III)Krabbe Disease (Globoid Leukodystrophy)Metachromatic Leukodystrophy (MLD)Adrenoleukodystrophy (ALD and AMN)Sandhoff DiseaseTay Sachs DiseasePelizaeus Merzbacher (PMD)Niemann-Pick DiseaseAlpha-mannosidosisNCT01372228Talaris Therapeutics Inc.3
撤回
1 期
Allogeneic Stem Cell Transplantation for the Treatment of Multiple SclerosisMultiple SclerosisNCT00497952Talaris Therapeutics Inc.
已完成
1 期
Induction of Donor Specific Tolerance in Recipients of Cardiac Allografts by Donor Stem Cell InfusionHeart TransplantationNCT00497757Suzanne T. Ildstad62
进行中（未招募）
1 期
Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell InfusionRenal FailureNCT00498160Talaris Therapeutics Inc.38